slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 20,971-21,000
Pages 1,064
Rows per page 30
Loop
20,971-21,000 of 31,900
16
The slide uses a combination of a product screenshot and four key metrics to validate the 'social commerce' thesis.Nextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
10
Includes footnotes regarding restricted cash, FFI acquisition, share registration, and adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
Includes footnotes detailing stock-based compensation components.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
12
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
13
Includes footnotes regarding order conditions and currency units.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
07
Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
Uses a structural biology diagram to illustrate mechanism of action.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The chart is a Kaplan-Meier survival curve showing the impact of fluid overload on patient outcomes.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
05
The slide uses a combination of bullet points, a comparison table, and a bar chart to build a market opportunity case.OmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit